ADVFN US – Market Content Editor
-

Bath & Body Works beats Q4 expectations, shares gain despite softer 2026 outlook
Bath & Body Works, Inc. (NYSE:BBWI) reported fourth-quarter results that came in above analyst forecasts, although the company warned that sales could decline in 2026 as it continues to reshape its business. The home fragrance retailer posted adjusted earnings per share of $2.05 for the quarter ended January 31, exceeding the analyst consensus estimate of…
-

Riskified tops earnings and revenue forecasts
Riskified Ltd. (NYSE:RSKD) reported fourth-quarter results on Wednesday that exceeded analyst expectations, with both earnings and revenue coming in ahead of forecasts. The company posted adjusted earnings per share of $0.12, beating the consensus estimate of $0.10 by $0.02. Revenue reached $99.33 million, surpassing the analyst forecast of $97.15 million and representing a 6% increase…
-

Box shares rise 6% after Q4 revenue beat and share buyback
Shares of Box Inc (NYSE:BOX) climbed 6.06% to $25.37 in premarket trading on Wednesday, rebounding from their lowest closing level since February 10 recorded in the previous session. The intelligent content management platform reported fourth-quarter revenue that came in slightly above analyst forecasts, according to data compiled by LSEG. During the quarter, Box repurchased 4.4…
-

Stevanato Group shares jump nearly 17% after strong fourth-quarter results
Stevanato Group S.p.A. (NYSE:STVN) reported fourth-quarter results on Wednesday that came in ahead of analyst expectations. Shares of the company surged 16.70% in after-hours trading following the announcement, as investors responded to continued strength in its high-value solutions segment. The Italian provider of drug containment and delivery systems reported adjusted diluted earnings per share of…
-

Ascent Industries shares drop after reporting fourth-quarter loss
Shares of Ascent Industries (NASDAQ:ACNT) fell 14.38% to $14.88 in premarket trading on Wednesday after the company reported a loss for the fourth quarter. The company recorded a net loss of $1 million for the quarter, compared with a profit of nearly $200,000 in the same period a year earlier. Chief Executive Officer Bryan Kitchen…
-

National Vision tops Q4 expectations, shares dip on cautious outlook
National Vision Holdings, Inc. (NASDAQ:EYE) reported fourth-quarter results on Wednesday that came in above analyst forecasts. Despite the stronger-than-expected performance, the company’s shares fell 1.09% in premarket trading as investors evaluated the retailer’s fiscal 2026 guidance relative to market expectations. The optical retailer reported adjusted earnings per share of $0.15 for the quarter, surpassing the…
-

CrowdStrike tops Q4 expectations, provides steady outlook for fiscal 2027
CrowdStrike (NASDAQ:CRWD) reported fourth-quarter results that exceeded Wall Street forecasts and issued guidance for fiscal 2027 that was broadly in line with market expectations, as investors continue to assess the impact of artificial intelligence on the software sector. Shares of the cybersecurity company rose 1.4% in U.S. premarket trading on Wednesday. The stock has declined…
-

Wix.com matches Q4 revenue expectations, forecasts mid-teens growth for 2026
Wix.com (NASDAQ:WIX) reported fourth-quarter revenue of $524.3 million, up 14% from a year earlier and broadly in line with analysts’ average estimate of $527.9 million, according to Bloomberg consensus data. The company posted non-GAAP operating income of $81.2 million for the quarter, exceeding the $77.1 million analysts had expected. Adjusted gross profit reached $358.8 million,…
-

GitLab shares slide after disappointing earnings guidance
Shares of GitLab (NASDAQ:GTLB) dropped 8.8% to $24.35 in premarket trading on Wednesday after the software development platform issued a fiscal 2027 earnings outlook that came in below Wall Street expectations. The company forecast adjusted earnings per share of between 76 cents and 80 cents for fiscal 2027, well under analysts’ consensus estimate of $1.05,…
-

Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute
Moderna (NASDAQ:MRNA) has reached a settlement worth up to $2.25 billion with Genevant Sciences, a subsidiary of Roivant Sciences (NASDAQ:ROIV), and Arbutus Biopharma (NASDAQ:ABUS), resolving a patent dispute tied to its COVID-19 vaccine. The agreement brings to an end multiple legal cases in the United States and internationally that alleged Moderna used lipid nanoparticle (LNP)…